New Body Fluid Application for the CellaVision DM96 now cleared for sale in the US

The application improves the efficiency, standardization and
connectivity of a difficult microscopic procedure

CellaVision AB (publ), which develops and sells digital morphology
products, has received clearance by the Food and Drug Administration
(FDA) to market and sell its CellaVision® Body Fluid Application, in
the US."The FDA clearance of our body fluid application will both increase
the utility of the CellaVision DM96 analyzer and the product
portfolio available to both new and existing customers on the US
market, and will reflect positively on our sales," says Yvonne
Mårtensson, CEO of CellaVision. "Additionally, FDA clearance is also
very important to many markets outside the US."

The CellaVision® Body Fluid Application runs on the analyzer
CellaVision® DM96. Most laboratories already using the analyzer for
blood differentials are also analyzing other body fluids, such as
cerebrospinal fluid and pleural fluid. The benefits are similar to
the company's blood application, namely quicker and more standardized
results, digital archiving of test results with cell images, as well
as sharing of digital images with experts outside the laboratory.

CellaVision's products are sold direct in the US by the subsidiary
CellaVision Inc. and are also distributed by Sysmex America. All
CellaVision DM96 analyzers that are already installed in the US form
potential bases for the body fluids application. The CellaVision®
Body Fluid Application is already available in Europe and Canada.


For more information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Phone: +46 708 33 77 82. E-mail: yvonne.martensson@cellavision.com


About CellaVision
CellaVision AB develops, markets, and sells market leading image
analysis based systems for routine analysis of blood and other body
fluids. The company has a core competence in development of software
and hardware for automatic image analysis of cells and cell changes
for applications in health and medical care. The company develops and
markets systems for automatic differentials of white blood cells and
red morphology, and software for education and quality assurance of
differentials. The company's associates have expertise in advanced
imaging analysis, artificial intelligence, and automated microscopy.

The company headquarters are in Lund, Sweden. The company also has
subsidiaries in Florida, USA, Toronto, Canada and Yokohama, Japan.
For more information, visit www.cellavision.com.

CellaVision's share is listed on First North at the OMX Stockholm
Stock Exchange. The company's Certified Advisor is Remium AB.